Minerva Neurosciences, Inc. (NERV)
Last updated: 2026-10-22 03:28:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Minerva Neurosciences, Inc. (NERV) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.41, with a market capitalization of $110.77M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.24 to $12.46. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$110.77M | |
$2.48 | |
$126.72 | |
$1.15 | |
$2.53 | |
71.08K | |
180.47K | |
-- | |
$12.46 | |
$2.24 | |
-- | |
-- |
Minerva Neurosciences, Inc. (NERV) Latest Closing Stock Price
Minerva Neurosciences, Inc. (NERV) last closed at $2.53 as of 2026-10-21 22:27:00, unchanged from the previous close of $2.53.
During the latest regular trading session, NERV traded between $1.15 and $126.72, with a volume of 71.08K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Minerva Neurosciences, Inc. (NERV) 7-Day Stock Price Change
Over the past seven days, Minerva Neurosciences, Inc. (NERV) moved from $2.89 to $2.41, representing a decline of 16.78% ($0.49).
The stock traded between $2.24 and $3.23 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 154.64 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
NERV 52-Week Price Position
Position in Range: 1.6%
NERV is currently trading at $2.41, placing it 1.6% of the way from its 52-week low of $2.24 to its 52-week high of $12.46. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Minerva Neurosciences, Inc. (NERV)?
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
Minerva Neurosciences, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Minerva Neurosciences, Inc. (NERV) Stock on MEXC
Eligible investors can buy real shares of Minerva Neurosciences, Inc. (NERV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Minerva Neurosciences, Inc. (NERV) stock price today?
2.Is NERV stock going up or down today?
3.What is NERV pre-market price?
4.What is NERV after-hours price?
5.Is NERV stock trading now?
6.Where does NERV sit relative to its 52-week high and low?
7.What sector is Minerva Neurosciences, Inc. in?
8.What is Minerva Neurosciences, Inc.'s market capitalization and where is it listed?
9.How is NERV valued in terms of P/E ratio and EPS?
10.Does Minerva Neurosciences, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
NERV Stock Calculator
Estimate the value between NERV shares and USD.
NERV Shares to USD
1.00 NERV shares = 2.405 USD
Calculations are estimates based on the latest available price and are for reference only.


